EUVIMEDEUVIMED entdecken
Crossref

Single locus HLA sequencing with the nanopore technology for HLA disease association diagnosis

Magali Devriese iD, Julien Rouquie, Sephora Da Silva, Nadine Benassaya, Lucie Maillard, Mathieu Dewez, Sophie Caillat-Zucman iD, Gregory Werner iD, Jean-Luc Taupin iD

HLA · 2024

DOI: 10.1111/tan.15424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HLA, 2024. Verfasst von Magali Devriese und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France. Hauptthemen laut MEDLINE: Nanopores. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Fondation pour la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Associations between HLA genotype and disease susceptibility encompass almost all the classic HLA loci. The level of typing resolution enabling a correct identification of an HLA disease susceptibility gene depends on the disease itself and/or on the accumulated knowledge about the molecular involvement of the HLA allele(s) engaged. Therefore, the application of Next Generation Sequencing technologies to HLA disease association, which would improve typing resolution, could prove useful to better understand disease severity. In the present study, we tested a nanopore sequencing approach developed by Omixon Biocomputing Ltd, dedicated to on‐demand locus typing for HLA and disease, as an alternative to the conventional widely used sequence specific oligoprobe (SSO) approach. A total of 145 DNA samples used in routine diagnosis by SSO were retrospectively analyzed with nanopore technology, for HLA‐A*02 immunotherapy decision for A*29 , B*27 , B*51 , B*57 identification in class I, and DRB1 , DQA1 , and DQB1 for bullous dermatosis, rheumatoid arthritis, diabetes, and celiac disease requests in class II. Each locus was typed in a separate experiment, except for DQB1 and DQA1, which were analyzed together. Concordance between typings reached 100% for all the loci tested. Ambiguities by nanopore were only found for missing exon coverage. This approach was found to be very well adapted to the routine flow imposed by the SSO technique. This study illustrates the use of the new NanoTYPE MONO kit for single locus HLA sequencing for HLA and disease association diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoporesHumansDisease SusceptibilityRetrospective StudiesHistocompatibility TestingAllelesHigh-Throughput Nucleotide SequencingHaplotypesGene Frequency

Stichwörter der Autor:innen

HLA and diseaseHLA typingNGSnanopore

Autor:innen und Institutionen

  • Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France.
  • INSERM UMR976, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
  • Omixon Biocomputing Ltd. H-1117 Budapest, Kaposvár, Hungary.

ORCID-Profile: Magali Devriese, Sophie Caillat-Zucman, Gregory Werner, Jean-Luc Taupin

Förderung

  • Fondation pour la Recherche Médicale

Zitieren

APA

Devriese, M., Rouquie, J., Da Silva, S., Benassaya, N., Maillard, L., Dewez, M., Caillat-Zucman, S., Werner, G., & Taupin, J. L. (2024). Single locus HLA sequencing with the nanopore technology for HLA disease association diagnosis. HLA. https://doi.org/10.1111/tan.15424

Vancouver

Devriese M, Rouquie J, Da Silva S, Benassaya N, Maillard L, Dewez M, et al. Single locus HLA sequencing with the nanopore technology for HLA disease association diagnosis. HLA. 2024. doi:10.1111/tan.15424

BibTeX
@article{Devriese2024,
  author = {Devriese, Magali and Rouquie, Julien and Da Silva, Sephora and Benassaya, Nadine and Maillard, Lucie and Dewez, Mathieu and Caillat-Zucman, Sophie and Werner, Gregory and Taupin, Jean-Luc},
  title = {Single locus HLA sequencing with the nanopore technology for HLA disease association diagnosis},
  journal = {HLA},
  year = {2024},
  doi = {10.1111/tan.15424}
}
Kostenlos starten →